A CDx deal for CC-122
BOULDER, Colo.—An agreement is underway between ArcherDX and Celgene Corp. for the development and commercialization of a next-generation sequencing-based oncology companion diagnostic (CDx) for Celgene’s CC-122 for indications in diffuse large B cell lymphoma (DLBCL). Per the agreement, ArcherDX will leverage its Anchored Multiplex PCR technology combined with the Illumina MiSeqDx sequencing system and Archer Analysis bioinformatics software to develop the CDx. The assay will be based on a proprietary gene expression signature Celgene developed to identify DLBCL patients most likely to respond to CC-122. Archer will retain worldwide rights to commercialize the CDx and will be responsible for all filings with regulatory bodies.
“We look forward to this collaboration arrangement with Celgene to deliver on the promise of precision medicine in a disease indication with high unmet medical need,” commented Jason Myers, CEO of ArcherDX.